A Phase 2 interventional study of Delpazolid and Vancomycin in MRSA Bacteremia, sponsored by LigaChem Biosciences, Inc.. Terminated at 6 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-05-06.
Sponsored by LigaChem Biosciences, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objectives of this study is to exploratory whether Vancomycin + Delpazolid is more effective to the standard of treatment (Vancomycin)/ for hospitalized adults with MRSA bacteraemia.
The mortality from S aureus bacteremia is higher for MRSA than for methicillin-susceptible S aureus (MSSA), typically at 20% to 25%.
The current standard therapy for MRSA bacteremia is Vancomycin. Vancomycin has many shortcomings, including poor tissue penetration and slow killing time. Vancomycin has reduced efficacy against MRSA and tended to increase the MIC level (called MIC creep). Addition of Delpazolid to Vancomycin could improve the known drawbacks of Vancomycin alone.
298 studies on the registry are indexed under Bacteremia; 50 are open to participants now.
This study's enrollment of 40 is below the median of 156 across 156 interventional studies indexed under Bacteremia.
Browse Bacteremia studies →LigaChem Biosciences, Inc. is the lead sponsor of 15 studies on the registry; 3 are open to participants now.
Compared within Bacteremia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sepsis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vancomycin: IV infusion per 2020 IDSA guideline * Intravenous Vancomycin dosed as per 2020 IDSA guideline * Doses of 15 to 20 mg/kg (based on actual body weight) administered every 8 to 12 hours as an intermittent infusion were recommended for most patients with normal renal function when assuming a MICBMD of 1 mg/L. * Depending on the investigator's judgment, it was allowed to change to Daptomycin after at least one week of administration of Vancomycin, and also it was allowed to change to oral antibiotics other than oxazolidinones after two weeks of administration of Vancomycin (including Daptomycin). Delpazolid: 800 mg, BID, PO
Drug: Delpazolid · Drug: Vancomycin
Vancomycin: IV infusion per 2020 IDSA guideline * Intravenous Vancomycin dosed as per 2020 IDSA guideline * Doses of 15 to 20 mg/kg (based on actual body weight) administered every 8 to 12 hours as an intermittent infusion were recommended for most patients with normal renal function when assuming a MICBMD of 1 mg/L. * Depending on the investigator's judgment, it was allowed to change to Daptomycin after at least one week of administration of Vancomycin, and also it was allowed to change to oral antibiotics other than oxazolidinones after two weeks of administration of Vancomycin (including Daptomycin). Placebo of Delpazolid: BID, PO
Drug: Vancomycin · Drug: Placebo of Delpazolid
BID, PO
Also known as: LCB01-0371
IV infusion per 2020 IDSA guideline
BID, PO
Also known as: Placebo of LCB01-0371
Overall Cure Rate at Day 14 After the Start of Treatment (Composite Response Rate: Clinical Improvement Plus Clearance of Bacteremia)_FAS
* 'Overall cure' means that there are no symptoms of infection that existed when enrolled in the clinical trial, there are no new metastatic infection due to MRSA and no new infection (clinical improvement), and MRSA negative is confirmed twice in a row as a result of blood culture tests (clearance of bacteremia). If negative in the blood culture test is confirmed for the first time, additional test will be performed the next day, and if it results negative for a total of two times in a row, it is judged as 'clearance of bacteremia'. * Composite Response rate = (number of participants showing overall cure at Day 14/number of participants in each treatment group) x 100
Time frame: at Day 14
Overall Cure Rate at Day 14 After the Start of Treatment (Composite Response Rate: Clinical Improvement Plus Clearance of Bacteremia)_PPS
* 'Overall cure' means that there are no symptoms of infection that existed when enrolled in the clinical trial, there are no new metastatic infection due to MRSA and no new infection (clinical improvement), and MRSA negative is confirmed twice in a row as a result of blood culture tests (clearance of bacteremia). If negative in the blood culture test is confirmed for the first time, additional test will be performed the next day, and if it results negative for a total of two times in a row, it is judged as 'clearance of bacteremia'. * Composite Response rate = (number of participants showing overall cure at Day 14/number of participants in each treatment group) x 100
Time frame: at Day 14
Overall Cure Rate by End of Treatment (EOT)_FAS
* 'Overall cure' means that there are no symptoms of infection that existed when enrolled in the clinical trial, there are no new metastatic infection due to MRSA and no new infection (clinical improvement), and MRSA negative is confirmed twice in a row as a result of blood culture tests (clearance of bacteremia). If negative in the blood culture test is confirmed for the first time, additional test will be performed the next day, and if it results negative for a total of two times in a row, it is judged as 'clearance of bacteremia'. * Composite Response rate = (number of participants showing overall cure at Day 14/number of participants in each treatment group) x 100
Time frame: Day 7 visit and EOT (up to 6 weeks) visit
Overall Cure Rate by End of Treatment (EOT)_PPS
* 'Overall cure' means that there are no symptoms of infection that existed when enrolled in the clinical trial, there are no new metastatic infection due to MRSA and no new infection (clinical improvement), and MRSA negative is confirmed twice in a row as a result of blood culture tests (clearance of bacteremia). If negative in the blood culture test is confirmed for the first time, additional test will be performed the next day, and if it results negative for a total of two times in a row, it is judged as 'clearance of bacteremia'. * Composite Response rate = (number of participants showing overall cure at Day 14/number of participants in each treatment group) x 100
Time frame: Day 7 visit and EOT (up to 6 weeks) visit
Mortality From MRSA Bacteremia by EOT_FAS
* Proportion of participants who died due to MRSA bacteremia * Overall mortality = (number of participants who died/number of participants in each treatment group) x 100
Time frame: During the treatment period (from the first administration to EOT (up to 6 weeks))
Mortality From MRSA Bacteremia by EOT_PPS
* Proportion of participants who died due to MRSA bacteremia * Overall mortality = (number of participants who died/number of participants in each treatment group) x 100
Time frame: During the treatment period (from the first administration to EOT (up to 6 weeks))
Relapse Rate of MRSA bacteremia_FAS
* Defined as a positive blood culture to MRSA when previous ones were negative * Relapse rate of MRSA bacteremia = (number of participants with Relapse of MRSA bacteremia after clearance of MRSA bacteremia until TOC visit/number of participants with clearance of MRSA bacteremia in each treatment group) x 100
Time frame: from the first administration to TOC (4 weeks after EOT)
Relapse Rate of MRSA bacteremia_PPS
* Defined as a positive blood culture to MRSA when previous ones were negative * Relapse rate of MRSA bacteremia = (number of participants with Relapse of MRSA bacteremia after clearance of MRSA bacteremia until TOC visit/number of participants with clearance of MRSA bacteremia in each treatment group) x 100
Time frame: from the first administration to TOC (4 weeks after EOT)
Clearance Rate of MRSA Bacteremia at Day 3, Day 5, Day 7, Day 14, EOT_FAS
* Proportion of participants who confirmed MRSA negative two consecutive set in the blood culture test * Clearance Rate = (number of subjects who achieved clearance at each visit/number of subjects in each treatment group) x 100
Time frame: Day 3, Day 5, Day 7, Day 14, EOT (up to 6 weeks)
Clearance Rate of MRSA Bacteremia at Day 3, Day 5, Day 7, Day 14, EOT_PPS
* Proportion of participants who confirmed MRSA negative two consecutive set in the blood culture test * Clearance Rate = (number of subjects who achieved clearance at each visit/number of subjects in each treatment group) x 100
Time frame: Day 3, Day 5, Day 7, Day 14, EOT (up to 6 weeks)
Persistent Rate of Bacteremia at Day 3, Day 5, Day 7, Day 14_FAS
* Proportion of participants who have positive results on blood culture tests * Persistent rate of bacteremia = (number of subjects who showing persistent bacteremia up to each visit /number of subjects in each treatment group up to each visit) x 100
Time frame: Day 3, Day 5, Day 7, Day 14
Persistent Rate of Bacteremia at Day 3, Day 5, Day 7, Day 14_PPS
* Proportion of participants who have positive results on blood culture tests * Persistent rate of bacteremia = (number of subjects who showing persistent bacteremia up to each visit /number of subjects in each treatment group up to each visit) x 100
Time frame: Day 3, Day 5, Day 7, Day 14
Time to Clearance of MRSA bacteremia_FAS
If negative in the blood culture test is confirmed for the first time, additional test will be performed the next day, and if it results negative for a total of two times in a row, it is judged as clearance of bacteremia. The period until the clearance of bacteremia is defined as the period (day) from the date of the first blood culture test within 72 hours prior to randomization with MRSA positive (index blood culture) to the date of the blood culture test with the first negative result confirmed.
Time frame: by EOT (up to 6 weeks)
Time to Clearance of MRSA bacteremia_PPS
If negative in the blood culture test is confirmed for the first time, additional test will be performed the next day, and if it results negative for a total of two times in a row, it is judged as clearance of bacteremia. The period until the clearance of bacteremia is defined as the period (day) from the date of the first blood culture test within 72 hours prior to randomization with MRSA positive (index blood culture) to the date of the blood culture test with the first negative result confirmed.
Time frame: by EOT (up to 6 weeks)
Vancomycin MIC Level
Vancomycin minimum inhibitory concentration (MIC) levels
Time frame: at Screening visit (baseline)
Delpazolid MIC Levels
Delpazolid minimum inhibitory concentration (MIC) level by broth microdilution (BMD)
Time frame: Screening (Baseline), Day 14, EOT
Pharmacokinetics (PK) parameters_AUC,ss
Plasma LCB01-0371 concentration data in MRSA bacteremia patients were used to establish a pharmacokinetic model using NONMEM®. A two-compartment model, in which the Hemodialysis (HD) status and albumin as a covariate, was selected as the final model. (AUC,ss: Area under the concentration-time curve at steady state)
Time frame: Plasma samples for pharmacokinetic evaluation were collected once at each timepoint on Day 1 and between Day 3 and end of treatment (EOT), specifically at 30 minutes to 1 hour and 2 to 8 hours after administration of the investigational product.
Pharmacokinetics (PK) parameters_Cmax,ss
Plasma LCB01-0371 concentration data in MRSA bacteremia patients were used to establish a pharmacokinetic model using NONMEM®. A two-compartment model, in which the Hemodialysis (HD) status and albumin as a covariate, was selected as the final model. (Cmax,ss: Maximum concentration of drug at steady state)
Time frame: Plasma samples for pharmacokinetic evaluation were collected once at each timepoint on Day 1 and between Day 3 and end of treatment (EOT), specifically at 30 minutes to 1 hour and 2 to 8 hours after administration of the investigational product.
Pharmacokinetics (PK) parameters_Cmin,ss
Plasma LCB01-0371 concentration data in MRSA bacteremia patients were used to establish a pharmacokinetic model using NONMEM®. A two-compartment model, in which the Hemodialysis (HD) status and albumin as a covariate, was selected as the final model. (Cmin,ss: Minimum concentration of drug at steady state)
Time frame: Plasma samples for pharmacokinetic evaluation were collected once at each timepoint on Day 1 and between Day 3 and end of treatment (EOT), specifically at 30 minutes to 1 hour and 2 to 8 hours after administration of the investigational product.
Pharmacokinetics (PK) parameters_Tmax,ss
Plasma LCB01-0371 concentration data in MRSA bacteremia patients were used to establish a pharmacokinetic model using NONMEM®. A two-compartment model, in which the Hemodialysis (HD) status and albumin as a covariate, was selected as the final model. (Tmax,ss: Time to reach Cmax at steady state)
Time frame: Plasma samples for pharmacokinetic evaluation were collected once at each timepoint on Day 1 and between Day 3 and end of treatment (EOT), specifically at 30 minutes to 1 hour and 2 to 8 hours after administration of the investigational product.
Pharmacokinetics (PK) parameters_t1/2β
Plasma LCB01-0371 concentration data in MRSA bacteremia patients were used to establish a pharmacokinetic model using NONMEM®. A two-compartment model, in which the Hemodialysis (HD) status and albumin as a covariate, was selected as the final model. (t1/2β : Terminal elimination half-life)
Time frame: Plasma samples for pharmacokinetic evaluation were collected once at each timepoint on Day 1 and between Day 3 and end of treatment (EOT), specifically at 30 minutes to 1 hour and 2 to 8 hours after administration of the investigational product.
Pharmacokinetics (PK) parameters_MRT,ss
Plasma LCB01-0371 concentration data in MRSA bacteremia patients were used to establish a pharmacokinetic model using NONMEM®. A two-compartment model, in which the Hemodialysis (HD) status and albumin as a covariate, was selected as the final model. (MRT,ss: Mean residence time at steady state)
Time frame: Plasma samples for pharmacokinetic evaluation were collected once at each timepoint on Day 1 and between Day 3 and end of treatment (EOT), specifically at 30 minutes to 1 hour and 2 to 8 hours after administration of the investigational product.
This study was initiated on 26 Apr 2022 (first signed informed consent) with the date of last participant who completed last study visit on 18 Mar 2024. A total of 45 participants were screened. Of these, 40 participants were randomized to 1 of 2 arms. The remaining 5 participants were considered to have been screen failures.
| Milestone | Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BID | Monotherapy - Vancomycin IV Plus Placebo of Delpazolid |
|---|---|---|
| Started | 20 | 20 |
| Safety set | 18 | 20 |
| Completed | 10 | 13 |
| Not completed | 10 | 7 |
| Withdrew: Withdrawal by subject | 4 | 3 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: If the following treatment failure criteria are met during treatment period | 1 | 2 |
| Withdrew: When investigators decide that the subject should stop participating in the trial for other reasons | 4 | 2 |
* 'Overall cure' means that there are no symptoms of infection that existed when enrolled in the clinical trial, there are no new metastatic infection due to MRSA and no new infection (clinical improvement), and MRSA negative is confirmed twice in a row as a result of blood culture tests (clearance of bacteremia). If negative in the blood culture test is confirmed for the first time, additional test will be performed the next day, and if it results negative for a total of two times in a row, it is judged as 'clearance of bacteremia'. * Composite Response rate = (number of participants showing overall cure at Day 14/number of participants in each treatment group) x 100
| Participants | Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BID | Monotherapy - Vancomycin IV Plus Placebo of Delpazolid |
|---|---|---|
| Overall Cure Rate at Day 14 After the Start of Treatment (Composite Response Rate: Clinical Improvement Plus Clearance of Bacteremia)_FAS | 9 | 10 |
* 'Overall cure' means that there are no symptoms of infection that existed when enrolled in the clinical trial, there are no new metastatic infection due to MRSA and no new infection (clinical improvement), and MRSA negative is confirmed twice in a row as a result of blood culture tests (clearance of bacteremia). If negative in the blood culture test is confirmed for the first time, additional test will be performed the next day, and if it results negative for a total of two times in a row, it is judged as 'clearance of bacteremia'. * Composite Response rate = (number of participants showing overall cure at Day 14/number of participants in each treatment group) x 100
| Participants | Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BID | Monotherapy - Vancomycin IV Plus Placebo of Delpazolid |
|---|---|---|
| Overall Cure Rate at Day 14 After the Start of Treatment (Composite Response Rate: Clinical Improvement Plus Clearance of Bacteremia)_PPS | 9 | 9 |
* 'Overall cure' means that there are no symptoms of infection that existed when enrolled in the clinical trial, there are no new metastatic infection due to MRSA and no new infection (clinical improvement), and MRSA negative is confirmed twice in a row as a result of blood culture tests (clearance of bacteremia). If negative in the blood culture test is confirmed for the first time, additional test will be performed the next day, and if it results negative for a total of two times in a row, it is judged as 'clearance of bacteremia'. * Composite Response rate = (number of participants showing overall cure at Day 14/number of participants in each treatment group) x 100
| Participants | Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BID | Monotherapy - Vancomycin IV Plus Placebo of Delpazolid |
|---|---|---|
| Day 7 | 7 | 6 |
| End of Treatment | 12 | 14 |
* 'Overall cure' means that there are no symptoms of infection that existed when enrolled in the clinical trial, there are no new metastatic infection due to MRSA and no new infection (clinical improvement), and MRSA negative is confirmed twice in a row as a result of blood culture tests (clearance of bacteremia). If negative in the blood culture test is confirmed for the first time, additional test will be performed the next day, and if it results negative for a total of two times in a row, it is judged as 'clearance of bacteremia'. * Composite Response rate = (number of participants showing overall cure at Day 14/number of participants in each treatment group) x 100
| Participants | Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BID | Monotherapy - Vancomycin IV Plus Placebo of Delpazolid |
|---|---|---|
| Day 7 | 6 | 5 |
| End of Treatment | 10 | 12 |
* Proportion of participants who died due to MRSA bacteremia * Overall mortality = (number of participants who died/number of participants in each treatment group) x 100
| Participants | Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BID | Monotherapy - Vancomycin IV Plus Placebo of Delpazolid |
|---|---|---|
| Overall death | 0 | 1 |
| Death from MRSA bacteremia | 0 | 0 |
* Proportion of participants who died due to MRSA bacteremia * Overall mortality = (number of participants who died/number of participants in each treatment group) x 100
| Participants | Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BID | Monotherapy - Vancomycin IV Plus Placebo of Delpazolid |
|---|---|---|
| Overall death | 0 | 1 |
| Death from MRSA bacteremia | 0 | 0 |
* Defined as a positive blood culture to MRSA when previous ones were negative * Relapse rate of MRSA bacteremia = (number of participants with Relapse of MRSA bacteremia after clearance of MRSA bacteremia until TOC visit/number of participants with clearance of MRSA bacteremia in each treatment group) x 100
| Participants | Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BID | Monotherapy - Vancomycin IV Plus Placebo of Delpazolid |
|---|---|---|
| Relapse Rate of MRSA bacteremia_FAS | 2 | 1 |
* Defined as a positive blood culture to MRSA when previous ones were negative * Relapse rate of MRSA bacteremia = (number of participants with Relapse of MRSA bacteremia after clearance of MRSA bacteremia until TOC visit/number of participants with clearance of MRSA bacteremia in each treatment group) x 100
| Participants | Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BID | Monotherapy - Vancomycin IV Plus Placebo of Delpazolid |
|---|---|---|
| Relapse Rate of MRSA bacteremia_PPS | 2 | 1 |
* Proportion of participants who confirmed MRSA negative two consecutive set in the blood culture test * Clearance Rate = (number of subjects who achieved clearance at each visit/number of subjects in each treatment group) x 100
| Participants | Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BID | Monotherapy - Vancomycin IV Plus Placebo of Delpazolid |
|---|---|---|
| Day3 | 8 | 6 |
| Day5 | 9 | 11 |
| Day7 | 7 | 6 |
| Day14 | 9 | 11 |
| End of Treatment | 12 | 14 |
* Proportion of participants who confirmed MRSA negative two consecutive set in the blood culture test * Clearance Rate = (number of subjects who achieved clearance at each visit/number of subjects in each treatment group) x 100
| Participants | Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BID | Monotherapy - Vancomycin IV Plus Placebo of Delpazolid |
|---|---|---|
| Day3 | 5 | 5 |
| Day5 | 8 | 8 |
| Day7 | 6 | 5 |
| Day14 | 9 | 10 |
| End of Treatment | 10 | 12 |
* Proportion of participants who have positive results on blood culture tests * Persistent rate of bacteremia = (number of subjects who showing persistent bacteremia up to each visit /number of subjects in each treatment group up to each visit) x 100
| Participants | Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BID | Monotherapy - Vancomycin IV Plus Placebo of Delpazolid |
|---|---|---|
| Day3 | 6 | 12 |
| Day5 | 4 | 7 |
| Day7 | 1 | 3 |
| Day14 | 0 | 2 |
* Proportion of participants who have positive results on blood culture tests * Persistent rate of bacteremia = (number of subjects who showing persistent bacteremia up to each visit /number of subjects in each treatment group up to each visit) x 100
| Participants | Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BID | Monotherapy - Vancomycin IV Plus Placebo of Delpazolid |
|---|---|---|
| Day3 | 5 | 9 |
| Day5 | 3 | 6 |
| Day7 | 0 | 3 |
| Day14 | 0 | 2 |
If negative in the blood culture test is confirmed for the first time, additional test will be performed the next day, and if it results negative for a total of two times in a row, it is judged as clearance of bacteremia. The period until the clearance of bacteremia is defined as the period (day) from the date of the first blood culture test within 72 hours prior to randomization with MRSA positive (index blood culture) to the date of the blood culture test with the first negative result confirmed.
| days | Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BID | Monotherapy - Vancomycin IV Plus Placebo of Delpazolid |
|---|---|---|
| Time to Clearance of MRSA bacteremia_FAS | 7.00 (3.00 to 14.00) | 8.00 (4.00 to 18.00) |
If negative in the blood culture test is confirmed for the first time, additional test will be performed the next day, and if it results negative for a total of two times in a row, it is judged as clearance of bacteremia. The period until the clearance of bacteremia is defined as the period (day) from the date of the first blood culture test within 72 hours prior to randomization with MRSA positive (index blood culture) to the date of the blood culture test with the first negative result confirmed.
| days | Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BID | Monotherapy - Vancomycin IV Plus Placebo of Delpazolid |
|---|---|---|
| Time to Clearance of MRSA bacteremia_PPS | 4.00 (3.00 to 14.00) | 7.00 (4.00 to 18.00) |
Vancomycin minimum inhibitory concentration (MIC) levels
| mcg/ml | Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BID | Monotherapy - Vancomycin IV Plus Placebo of Delpazolid |
|---|---|---|
| Vancomycin MIC Level | 0.78 ± 0.256 | 0.75 ± 0.258 |
Delpazolid minimum inhibitory concentration (MIC) level by broth microdilution (BMD)
| mcg/ml | Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BID | Monotherapy - Vancomycin IV Plus Placebo of Delpazolid |
|---|---|---|
| Baseline | 1.1 ± 0.34 | 1.1 ± 0.42 |
| Day14 | 1.0 ± NA | 1.0 ± 0.00 |
| End of Treatment | 1.0 ± NA | — |
Plasma LCB01-0371 concentration data in MRSA bacteremia patients were used to establish a pharmacokinetic model using NONMEM®. A two-compartment model, in which the Hemodialysis (HD) status and albumin as a covariate, was selected as the final model. (AUC,ss: Area under the concentration-time curve at steady state)
| ng*h/mL | Total | No ESRD | ESRD | Not Undergoing HD | Undergoing HD | No HI/LC | HI/LC |
|---|---|---|---|---|---|---|---|
| Pharmacokinetics (PK) parameters_AUC,ss | 90,855.222 ± 88,895.538 | 83,671.053 ± 75,411.511 | 99,065.701 ± 107,966.645 | 112,462.317 ± 111,518.903 | 58,444.580 ± 11,292.560 | 59,842.551 ± 26,423.362 | 152,880.564 ± 137,383.144 |
Plasma LCB01-0371 concentration data in MRSA bacteremia patients were used to establish a pharmacokinetic model using NONMEM®. A two-compartment model, in which the Hemodialysis (HD) status and albumin as a covariate, was selected as the final model. (Cmax,ss: Maximum concentration of drug at steady state)
| ng/mL | Total | No ESRD | ESRD | Not Undergoing HD | Undergoing HD | No HI/LC | HI/LC |
|---|---|---|---|---|---|---|---|
| Pharmacokinetics (PK) parameters_Cmax,ss | 8,595.050 ± 7,229.136 | 8,610.266 ± 5,715.031 | 8,577.661 ± 9,156.152 | 10,903.652 ± 8,712.950 | 5,132.147 ± 938.601 | 6,216.075 ± 1,624.925 | 13,353.002 ± 11,598.454 |
Plasma LCB01-0371 concentration data in MRSA bacteremia patients were used to establish a pharmacokinetic model using NONMEM®. A two-compartment model, in which the Hemodialysis (HD) status and albumin as a covariate, was selected as the final model. (Cmin,ss: Minimum concentration of drug at steady state)
| ng/mL | Total | No ESRD | ESRD | Not Undergoing HD | Undergoing HD | No HI/LC | HI/LC |
|---|---|---|---|---|---|---|---|
| Pharmacokinetics (PK) parameters_Cmin,ss | 6,586.689 ± 7,255.844 | 5,541.150 ± 6,209.527 | 7,781.590 ± 8,644.985 | 7,955.430 ± 9,284.244 | 4,533.576 ± 1,032.638 | 3,992.895 ± 2,331.779 | 11,774.277 ± 11,026.039 |
Plasma LCB01-0371 concentration data in MRSA bacteremia patients were used to establish a pharmacokinetic model using NONMEM®. A two-compartment model, in which the Hemodialysis (HD) status and albumin as a covariate, was selected as the final model. (Tmax,ss: Time to reach Cmax at steady state)
| h | Total | No ESRD | ESRD | Not Undergoing HD | Undergoing HD | No HI/LC | HI/LC |
|---|---|---|---|---|---|---|---|
| Pharmacokinetics (PK) parameters_Tmax,ss | 3.562 ± 1.322 | 3.083 ± 1.515 | 4.110 ± 0.861 | 3.286 ± 1.542 | 3.978 ± 0.861 | 3.291 ± 1.429 | 4.105 ± 0.984 |
Plasma LCB01-0371 concentration data in MRSA bacteremia patients were used to establish a pharmacokinetic model using NONMEM®. A two-compartment model, in which the Hemodialysis (HD) status and albumin as a covariate, was selected as the final model. (t1/2β : Terminal elimination half-life)
| h | Total | No ESRD | ESRD | Not Undergoing HD | Undergoing HD | No HI/LC | HI/LC |
|---|---|---|---|---|---|---|---|
| Pharmacokinetics (PK) parameters_t1/2β | 9,292.011 ± 28,745.858 | 1,689.649 ± 4,369.248 | 17,980.425 ± 41,721.541 | 13,973.252 ± 37,076.761 | 2,270.149 ± 3,949.333 | 425.392 ± 572.107 | 27,025.249 ± 47,976.785 |
Plasma LCB01-0371 concentration data in MRSA bacteremia patients were used to establish a pharmacokinetic model using NONMEM®. A two-compartment model, in which the Hemodialysis (HD) status and albumin as a covariate, was selected as the final model. (MRT,ss: Mean residence time at steady state)
| h | Total | No ESRD | ESRD | Not Undergoing HD | Undergoing HD | No HI/LC | HI/LC |
|---|---|---|---|---|---|---|---|
| Pharmacokinetics (PK) parameters_MRT,ss | 6,843.719 ± 20,060.037 | 1,159.389 ± 3,024.815 | 13,340.095 ± 28,912.833 | 9,730.567 ± 25,868.738 | 2,513.446 ± 4,304.084 | 436.814 ± 654.947 | 19,657.528 ± 33,160.057 |
Collected over From IP administration to TOC (Test of Cure, 4 weeks after EOT*), approximately 10 weeks *EOT (End of treatment): up to 6 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BID | 0/18 (0%) | 0/18 (0%) | 13/18 (72.2%) |
| Monotherapy - Vancomycin IV Plus Placebo of Delpazolid | 1/20 (5%) | 1/20 (5%) | 16/20 (80%) |
| Event | Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BID | Monotherapy - Vancomycin IV Plus Placebo of Delpazolid |
|---|---|---|
| end stage renal diseaseRenal and urinary disorders | 0/18 | 1/20 |
| Event | Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BID | Monotherapy - Vancomycin IV Plus Placebo of Delpazolid |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 5/18 | 0/20 |
| AnaemiaBlood and lymphatic system disorders | 3/18 | 5/20 |
| ConstipationGastrointestinal disorders | 1/18 | 3/20 |
| PruritusSkin and subcutaneous tissue disorders | 1/18 | 3/20 |
| COVID-19Infections and infestations | 2/18 | 0/20 |
| HypertensionVascular disorders | 2/18 | 0/20 |
| PyrexiaGeneral disorders | 2/18 | 1/20 |
| Adrenal insufficiencyEndocrine disorders | 2/18 | 0/20 |
| Melaena 0 [0] 2 (10.00) [2]Gastrointestinal disorders | 0/18 | 2/20 |
| Urinary tract infectionInfections and infestations | 0/18 | 2/20 |
Safety Set (SS)
| Age, Categorical(Participants) | Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BID | Monotherapy - Vancomycin IV Plus Placebo of Delpazolid | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 5 | 10 | 15 |
| >=65 years | 13 | 10 | 23 |
| Age, Continuous(years) | Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BID | Monotherapy - Vancomycin IV Plus Placebo of Delpazolid | Total |
|---|---|---|---|
| Mean | 69.3 ± 9.68 | 64.5 ± 16.47 | 66.8 ± 13.73 |
| Sex: Female, Male(Participants) | Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BID | Monotherapy - Vancomycin IV Plus Placebo of Delpazolid | Total |
|---|---|---|---|
| Female | 7 | 10 | 17 |
| Male | 11 | 10 | 21 |
| Race and Ethnicity Not Collected(Participants) | Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BID | Monotherapy - Vancomycin IV Plus Placebo of Delpazolid | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Childbearing potential(Participants) | Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BID | Monotherapy - Vancomycin IV Plus Placebo of Delpazolid | Total |
|---|---|---|---|
| Yes | 0 | 2 | 2 |
| No | 7 | 8 | 15 |
| Height (cm)(cm) | Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BID | Monotherapy - Vancomycin IV Plus Placebo of Delpazolid | Total |
|---|---|---|---|
| Mean | 164.15 ± 6.302 | 161.85 ± 7.582 | 162.94 ± 7.009 |
| Weight (kg)(kg) | Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BID | Monotherapy - Vancomycin IV Plus Placebo of Delpazolid | Total |
|---|---|---|---|
| Mean | 64.77 ± 9.536 | 63.59 ± 13.256 | 64.14 ± 11.506 |
| BMI (kg/m2)(kg/m^2) | Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BID | Monotherapy - Vancomycin IV Plus Placebo of Delpazolid | Total |
|---|---|---|---|
| Mean | 24.020 ± 3.1754 | 24.229 ± 4.6732 | 24.130 ± 3.9823 |
4 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Deidentified individual patient data, that underlie the results in published article(s) based on data from the trial which including text, tables, figures will be presented to various stakeholders. This reported will be presented to various stakeholder during various forums or meetings. First results will be disclosed to participants, staff and our site Community Advisory Board. Thereafter we would invite several stakeholders from the community or visit their establishments to review study results. Simultaneously, the studying findings report will be sent to the various regulatory authorities, including the National Department of Health (NDoH). With NDoH and its divisions we will establish needs for further engagement and suggestions for policy or programmatic changes.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be provided 1-2 years after and up to 5 years after the publication of the article on the results of the trial.
Access criteria: IPD access will be provided for analyses of the related to the aims of research described in the protocol and for individual patient data meta analyses to researches who provide a methodologically sound proposal to lcb_pv@legochembio.com
Ran from Apr 2022 to primary completion in Feb 2024, 21 months.
Results were first posted in May 2025, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Delpazolid
LigaChem Biosciences, Inc.